CAR T cell therapy has emerged as a revolutionary therapeutic option for multiple myeloma, with two recent FDA approvals7,8 targeting B cell maturation antigen (BCMA), a member of the TNF receptor superfamily9. Here, TNFRSF17 is linked to plasma cell myeloma.